Wed.Nov 13, 2024

article thumbnail

BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink

Fierce Pharma

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term. | As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term, according to a new loss of exclusivity report from Leerink Partners.

357
357
article thumbnail

How One Optum Exec Is Handling the Influx of Digital Mental Health Solutions

MedCity News

There has been a surge in digital mental health solutions, making it difficult to know which ones are effective. One Optum exec weighed in on how she’s managing this challenge. The post How One Optum Exec Is Handling the Influx of Digital Mental Health Solutions appeared first on MedCity News.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years

Fierce Pharma

Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years fkansteiner Wed, 11/13/2024 - 14:37

Patients 317
article thumbnail

Gilead data lends insight into transforming HIV prevention landscape

European Pharmaceutical Review

New clinical trial findings show that twice-yearly lenacapavir for HIV pre-exposure prophylaxis (PrEP) had high efficacy and safety in a diverse group of participants. This data provides the first in-depth insight into full results of Gilead Sciences pivotal Phase III PURPOSE 2 trial. In the oral PrEP study group, adherence to the small molecule injectable HIV-1 capsid inhibitor and placebo injections was 91.0 percent with on-time injections at week 26, the results showed.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

AstraZeneca and Merck's Koselugo delivers phase 3 trial win in adults with NF1, teeing up filings

Fierce Pharma

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1), AstraZeneca is touting a trial result that could allow the company and | Four years after scoring an FDA approval to treat children with NF1, AstraZeneca says its Merck-partnered Koselugo has shown promise in adults.

FDA 289
article thumbnail

London "is number one European city in life sciences"

pharmaphorum

London is the top city in Europe for the life sciences industry, and ranks third worldwide after Boston and New York in the US, says MedCity report

99

More Trending

article thumbnail

BioNTech buys Biotheus and its Keytruda rival for $950m

pharmaphorum

BioNTech buys Biotheus and its Keytruda rival for $950m Phil.

99
article thumbnail

Pfizer considers divestiture of hospital drugs business

Pharmaceutical Technology

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics and sterile injectables used in hospitals and clinics, Reuters reported.

98
article thumbnail

Sanofi wins appeal in spat with NICE over Sarclisa

pharmaphorum

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM).The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside Bristol-Myers Squibb/Celgene's Imnovid (pomalidomide) and dexamethasone (Isa-Pd) for relapsed RRMM.

105
105
article thumbnail

Microbiotica begins human trials for ulcerative colitis treatment

PharmaTimes

First patient dosed in phase 1b trial of MB310 therapy

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

PTC gets FDA okay for first brain-delivered gene therapy

pharmaphorum

More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US.The FDA has approved PTC's eladocagene exuparvovec – known as Upstaza in Europe – under the Kebilidi trade name in the US. It is cleared for both children and adults with AADC (aromatic L-amino acid decarboxylase) deficiency, a fatal disease that causes severe disability and suffering from the first months of life.

FDA 104
article thumbnail

Vivolta and Neurochase to produce brain therapy catheters

PharmaTimes

New long-term partnership to address neurological disorder treatments

90
article thumbnail

Amgen plays down safety concern with obesity candidate

pharmaphorum

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density

Safety 88
article thumbnail

From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies

PharmaVoice

As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court

MedCity News

Johnson & Johnson is suing the federal agencies overseeing the 340B program that makes discounted medicines more accessible to uninsured and underserved patients. J&J contends the Health Resources Services Administration can’t legally oppose its plan to implement a new rebate plan for certain 340B drugs. The post Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court appeared first on MedCity News.

article thumbnail

Pharma Pulse 11/13/24: Strategies for Bridging the Sponsor-Site Tech Divide, Innovative Approaches to Chronic Disease Management & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 59
article thumbnail

What Will Happen if Millions of Americans Lose Access to GLP-1s at the Same Time?

Pharmacy Times

There has never been such widespread and popularized use of compounded products due to shortages. Will consumers rise up with pitchforks if the party is shut down?

58
article thumbnail

Proton's Transformation: How Malaysia's Auto Giant Learned to Create Its Own Future

Contrarian Sales Techniques

"The best way to predict the future is to create it." - Philip Kotler When marketing legend Philip Kotler said these words, he could have been speaking directly to Malaysian businesses facing the winds of change. In a world where prediction seems impossible, Kotler suggests something revolutionary: don't just prepare for the future – shape it. Consider the fascinating story of Proton's evolution.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

The Role of Clinical Specialists in Cardiac Rhythm Management With Greg Olson

Evolve Your Success

Join me for a fascinating conversation with Greg Olson, a seasoned expert from Medtronic, as we uncover the intricate world of medical sales, specifically focusing on cardiac rhythm management (CRM). Greg, having devoted 25 years to the company, shares his invaluable insights as a Senior District Service Manager, leading a dedicated team of clinical specialists.

article thumbnail

Global Disparities in Cancer Burden

Pharmaceutical Commerce

A cross-sectional study uses epidemiological patterns to investigate these disparities, while also predicting the potential shift of these patterns by 2050.

52
article thumbnail

Koselugo Demonstrates Clinically Meaningful Improvement in Adults with Symptomatic, Inoperable Plexiform Neurofibromas

PharmExec

Results from the Phase III KOMET trial found that Koselugo demonstrated a statistically significant objective response rate compared to placebo treating plexiform neurofibromas.

52
article thumbnail

Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint 

Pharmaceutical Technology

Syndax shared topline data from its Phase II AUGMENT-101 trial, but the results failed to convince investors.

52
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Navigating the Current Landscape for Pharma Leaders

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Pharma 52
article thumbnail

Cryoport Opens New CoE in Europe

Pharmaceutical Commerce

The 13,400 square-foot Belgium site will expand the company’s branded standardized bioprocessing, cryopreservation, and distribution solution for the cell therapy market, with a focus on leukapheresis starting materials.

article thumbnail

Powering Pipelines Forward: Approach Science Differently

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

Syros stock craters after lead cancer therapy flops in Phase III trial

Pharmaceutical Technology

The company plans to discontinue the study after the combination therapy failed to meet the primary endpoint in the Phase III trial.

Leads 52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Passage to Asia: Early Access for Innovative Therapies

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

Intercept loses Ocaliva FDA full approval bid in rare liver disease

Pharmaceutical Technology

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease treatment.

FDA 52
article thumbnail

BioNTech SE Strikes Deal to Acquire Biotheus

PharmExec

As part of the acquisition, BioNTech will obtain the rights to BNT327/PM8002, a bispecific antibody that targets PD-L1-low and -negative tumors that often resist checkpoint inhibitors.

52
article thumbnail

The development of novel drugs: the role of lyophilization

Pharmaceutical Technology

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it be mastered?

52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A